Conference Proceedings
Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial
Leisha Emens, Luciana Molinero, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Veronique Dieras, Hiroji Iwata, Carlos Barrios, Eric P Winer, Ching-Wei Chang, Stephen Y Chui, Peter Schmid, Sherene Loi
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
Abstract
Abstract Background: The clinical implications of genomic alterations in metastatic triple-negative breast cancer (mTNBC) have not been clearly addressed. In IMpassion130, atezolizumab (A) + nab-paclitaxel (nP) showed improved progression-free survival (PFS) and clinically meaningful overall survival (OS) benefit vs placebo (P) + nP in PD-L1+ mTNBC (Schmid, NEJM 2018). The goal of this exploratory study was to evaluate the prevalence of genomic alterations and their relationship with PD-L1 status and to determine whether a prognostic or predictive role for these factors exists for A + nP in a randomized dataset. Methods: Primary or metastatic tumor samples from patients in the..
View full abstract